Evaluation of iron‐chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron‐chelating drug

Chaim Hershko*, Robert W. Grady, Gabriela Link

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Summary. Fifteen compounds with a high affinity to ferric iron have been screened for in vivo iron‐chelating efficiency in a rat model. One of the most potent of these drugs was ethylenediamine‐N,N′‐bis(o‐hydroxyphenylglycine) (EHPG). EHPG‐induced iron excretion was up to 8 times higher than iron excretion induced by identical doses of desferrioxamine (DF). Studies employing selective radio‐iron probes of reticuloendothelial and parenchymal iron stores showed that although EHPG is able to interact with both storage iron compartments, its effect on parenchymal iron is much more pronounced. Unlike DF which has two alternative routes of excretion, EHPG‐induced iron excretion is restricted mainly to the gut. Although EHPG seems to be superior to DF in both its chelating efficiency and preferential interaction with hepatic parenchymal iron stores, information on its in vivo toxicity is at present insufficient and it cannot yet be recommended for clinical use.

Original languageAmerican English
Pages (from-to)251-260
Number of pages10
JournalBritish Journal of Haematology
Volume51
Issue number2
DOIs
StatePublished - Jun 1982

Fingerprint

Dive into the research topics of 'Evaluation of iron‐chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron‐chelating drug'. Together they form a unique fingerprint.

Cite this